Shen L, Lorand L
J Clin Invest. 1983 May;71(5):1336-41. doi: 10.1172/jci110885.
The contribution of fibrin stabilization to clot strength, measured as the static elastic modulus, was evaluated in human plasma by two independent procedures. In the first approach, amine inhibitors of fibrin stabilization were examined for their effects on the rigidity of normal plasma clots. It is a unique property of these inhibitors that they do not interfere with the reversible aggregation of fibrin molecules, i.e., do not delay clotting time, but selectively prevent only the formation of gamma-glutamyl-epsilon-lysine protein-to-protein linkages. Though the compounds tested were of different chemical structures and potencies, a fivefold reduction in clot strength was obtained in each instance. This value of 20% of normal seems to correspond to the rigidity of the Factor XIII-deficient plasma clot because, as demonstrated by the second approach, when a plasma specimen that genetically lacked the fibrin stabilizing factor was supplemented by the addition of measured amounts of the purified zymogen, a fivefold increase in clot strength could be achieved. The described procedure of evaluating Factor XIII in terms of correcting the elastic modulus of a deficient plasma clot is considered an important assay for the functional competence of purified preparations of the zymogen for the purpose of therapeutic application.
通过两种独立的方法在人血浆中评估了纤维蛋白稳定对以静态弹性模量衡量的凝块强度的贡献。在第一种方法中，研究了纤维蛋白稳定的胺类抑制剂对正常血浆凝块硬度的影响。这些抑制剂的独特性质在于它们不会干扰纤维蛋白分子的可逆聚集，即不会延迟凝血时间，而是仅选择性地阻止γ-谷氨酰-ε-赖氨酸蛋白间键的形成。尽管所测试的化合物具有不同的化学结构和效力，但在每种情况下凝块强度都降低了五倍。正常强度的20%这一数值似乎与缺乏因子XIII的血浆凝块的硬度相对应，因为正如第二种方法所表明的，当向基因上缺乏纤维蛋白稳定因子的血浆样本中添加适量的纯化酶原时，凝块强度可提高五倍。就校正缺陷血浆凝块的弹性模量而言，所描述的评估因子XIII的方法被认为是一种重要的检测方法，用于评估纯化酶原制剂在治疗应用中的功能活性。
